Ocular Wnt/&#x3B2;-Catenin Pathway Inhibitor XAV939-Loaded Liposomes for Treating Alkali-Burned Corneal Wound and Neovascularization

RECOMMENDED

Cornea and Corneal DiseasesLenses

Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization

Ocul Surf.

Yin J, Jacobs DS

doi: 10.1016/j.jtos.2018.11.008.

Cornea and Corneal DiseasesGlaucoma and Ocular PressureOcular OncologyRetinal DiseasesSurgery and Intervention

Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension

Ophthalmology.

Tanna AP, Johnson M

doi: 10.1016/j.ophtha.2018.04.040.

Conjunctivitis

Epidemiologic Trends of Chemical Ocular Burns in the United States

JAMA Ophthalmol.

Haring RS, Sheffield ID, Channa R, Canner JK, Schneider EB

doi: 10.1001/

COMMENTED

Macular Diseases

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab Using a Treat and Extend Regimen: FLUID Study 24 Month Results

Ophthalmology.

Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ; FLUID Investigators

doi: 10.1016/j.ophtha.2018.11.025.

Macular Diseases

Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study

Acta Ophthalmol

Saenz-de-Viteri M, Recalde S, Fernandez-Robredo P, López Gálvez MI, Arias Barquet L, Figueroa MS, García-Arumí J, García-Layana A, In-Eye Study Group.

doi: 10.1111/aos.14786

Ocular Oncology

Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients with Uveal Melanoma Treated with Proton Beam Therapy

Int J Radiat Oncol Biol Phys.

Lee HJ Jr, Stacey A, Klesert TR, Wells C, Skalet A, Bloch C, Fung A, Bowen SR, Wong TP, Shibata D, Halasz LM, Rengan R

doi: 10.1016/j.ijrobp.2019.02.005.

Cornea and Corneal Diseases

Repeat Corneal Neovascularization is Characterized by More Aggressive Inflammation and Vessel Invasion Than in the Initial Phase

Invest Ophthalmol Vis Sci.

Mukwaya A, Mirabelli P, Lennikov A, Thangavelu M, Jensen L, Peebo B, Lagali N

doi: 10.1167/iovs.19-27591.

Macular Diseases

SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina.

Vittorio AF, Nguyen V, Barthelmes D, Arnold JJ, Cheung CMG, Murray N, Gillies MC, Fight Retinal Blindness! Study Group.

doi: 10.1097/IAE.0000000000002679.

Macular Diseases

Outcomes of Anti–Vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization in Fellow Eyes of Previously Treated Patients With Neovascular Age-Related Macular Degeneration

JAMA Ophthalmol.

Stem MS, Moinuddin O, Kline N, Thanos A, Rao P, Williams GA, Hassan TS

Related content

Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization

Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension

Epidemiologic Trends of Chemical Ocular Burns in the United States

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab Using a Treat and Extend Regimen: FLUID Study 24 Month Results

Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study

Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients with Uveal Melanoma Treated with Proton Beam Therapy

Repeat Corneal Neovascularization is Characterized by More Aggressive Inflammation and Vessel Invasion Than in the Initial Phase

SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Outcomes of Anti–Vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization in Fellow Eyes of Previously Treated Patients With Neovascular Age-Related Macular Degeneration